Newsroom

SEATTLE & LAKE CHARLES, La.--(BUSINESS WIRE)--Saltchuk Marine, LLC and Harbor Docking & Towing (HDT) today announced the formation of Green Tug Towing (GTT), a new joint venture company established to provide towage, escort, and terminal support services in the United States. GTT has been awarded a 20-year services contract by Woodside Energy to design, build, and operate four advanced hybrid escort tugboats to support LNG carrier operations at the company’s new Calcasieu Parish terminal. A...

TORONTO--(BUSINESS WIRE)--Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN) announced today that its board of trustees has declared a distribution of CDN $0.2958 per unit for the month of April 2026. The distribution will be paid by Granite on May 15, 2026 to unitholders of record at the close of trading on April 30, 2026. Granite confirms that no portion of the distribution constitutes effectively connected income for U.S. federal tax purposes. A qualified notice providing the bre...

DALLAS--(BUSINESS WIRE)--Celanese Announces Engineered Materials Price Increase...

NEW YORK--(BUSINESS WIRE)--DWS, a leading European asset manager with global reach, today announced the impending closure and liquidation of two Xtrackers ETFs: Xtrackers Risk Managed USD High Yield Strategy ETF (NYSE: HYRM) and Xtrackers California Municipal Bond ETF (NASDAQ: CA). Xtrackers Risk Managed USD High Yield Strategy ETF is listed on NYSE. After the close of business on May 7, 2026, the fund will no longer accept creation orders and will end trading. The fund will accept redemption o...

CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics maakte vandaag de afronding bekend van een follow-on financiering van $11 miljoen, waarmee het totaal van het opgehaalde kapitaal op $36 miljoen komt. Deze financiering ondersteunt de continue vorderingen van haar uitstekende geneesmiddel tegen het BK-polyomavirus. BK-virusinfecties zijn een belangrijke oorzaak van complicaties bij patiënten die een transplantatie hebben ondergaan, waarvoor geen goedgekeurde behandelingen bestaan. Het bedrij...

HARTFORD, Conn.--(BUSINESS WIRE)--Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the “Fund”) today announced that its Board of Trustees has approved a tender offer (“Tender Offer”) intended to enhance shareholder value, provide shareholders with an additional source of liquidity for their investment, and provide the potential to reduce the Fund’s trading discount to its net asset value per share (“NAV”). Pursuant to the terms of the Tender Offer, the Fund will offer to purch...

LEWISVILLE, Texas--(BUSINESS WIRE)--Davidson Bogel Real Estate (DB2RE) successfully facilitated the acquisition of an 8.5-acre, four-owner industrial land assemblage located at 421, 451, 475, and 493 Bennett Lane in Lewisville. The site was acquired by Lovett Industrial and is planned for the development of a Class A industrial project. The development aligns with the City of Lewisville’s evolving regulatory framework for industrial uses. The transaction was facilitated by Philip Cherrick of Da...

ATLANTA--(BUSINESS WIRE)--Repay Holdings Corporation (NASDAQ: RPAY) (“REPAY” or the “Company”), a leading provider of integrated payment processing solutions, today confirmed receipt of an unsolicited, non‑binding proposal from Forager Capital Management, LLC (“Forager Capital”), a stockholder of the Company, to acquire the outstanding shares of the Company for $4.80 per share in cash. REPAY’s Board of Directors (the “Board”), consistent with its fiduciary duties, will review the proposal in co...

CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics oggi ha annunciato la chiusura di un finanziamento aggiuntivo di 11 milioni di dollari, portando a 36 milioni di dollari il totale del capitale raccolto. Questo finanziamento sostiene l'ulteriore sviluppo del suo farmaco all'avanguardia contro il poliomavirus BK. Le infezioni da virus BK sono una importante causa di complicanze nei pazienti sottoposti a trapianto, per le quali non esistono terapie approvate. L'azienda sta introducendo una te...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, MiNK’s allo-iNKT cell therapy, ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer...